Neurobiological aspects of Alzheimer's disease

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 5, 2011, Pages 535-555

  Chopra, Kanwaljit ^a   Misra, Shubham ^a   Kuhad, Anurag ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Alzheimer's disease; animal models; pathobiology; pharmacotherapy

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID BETA VACCINE; ANTIAMYLOID AGENT; ANTIOXIDANT; BERBERINE; CANNABINOID DERIVATIVE; CHOLINESTERASE INHIBITOR; CURCUMIN; DIMEBON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; ESTROGEN; FERULIC ACID; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEMANTINE; NERVE GROWTH FACTOR; NEUROTOXIN; NEUROTROPHIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE INHIBITOR; RESVERATROL; RIVASTIGMINE; SELEGELINE; TACRINE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; XALIPRODEN;

AEROBIC METABOLISM; AGING; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ASTROCYTE; BIOSYNTHESIS; CAT; CELL ACTIVATION; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; DEMENTIA; DISEASE MARKER; DISEASE MODEL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TARGETING; EXCITOTOXICITY; EXPERIMENTAL MODEL; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; MICROGLIA; MICROTUBULE ASSEMBLY; MITOCHONDRION; NERVE CELL; NERVE CELL LESION; NERVE DEGENERATION; NEURITIS; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RABBIT; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TRANSGENIC ANIMAL; VACCINATION;

ALUMINUM; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; INFLAMMATION; MITOCHONDRIA; OKADAIC ACID; OXIDATIVE STRESS; TAU PROTEINS;

EID: 79954473644     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.557363     Document Type: Review

References (121)

1. Campbell VA, Gowran A. Alzheimer's disease; taking the edge off with cannabinoids? Br J Pharmacol 2007;152:655-61
2. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am 2005;15:727-53 (Pubitemid 43162374)
3. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499-509
4. Yates D, McLoughlin DM. The molecular pathology of Alzheimer's disease. Psychiatry 2008;7:1-5
5. Yin YY, Liu H, Cong XB, et al. Acetyl-L-Carnitine attenuates okadaic acid induced Tau hyperphosphorylation and spatial memory impairment in rats. J Alzheimer Dis 2010;19(2):735-46
6. Darvesh AS, Carroll RT, Bishayee A, et al. Oxidative stress and Alzheimers disease: dietary polyphenols as potential therapeutic agents. Expert Rev Neurother 2010;10:729-45
7. Vasto S, Candore G, List F, et al. Inflammation, genes and zinc in Alzheimer's disease. Brain Res Rev 2008;58:96-105
8. Buttini M, Masliah E, Barbour R, et al. beta-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005;25(40):9096-10007
9. Cacabelos R Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat 2007;3:303-10
10. Zhu X, Lee H, Perry G, et al. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 2007;1772:494-502 (Pubitemid 46400383)
11. Zhu X, Raina AK, Perry G, et al. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 2004;3:219-26 (Pubitemid 38373660)
12. Hua X, Lei M, Ding J, et al. Pathological and biochemical alterations of astrocytes in ovariectomized rats injected with D-galactose: a potential contribution to Alzheimer's disease processes. Exp Neurol 2008;210:709-18
13. Volpicelli-Daley LA, Duysen EG, Lockridge O, et al. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Ann Neurol 2003;53:788-96 (Pubitemid 36622517)
14. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-71
15. Gron G, Brandenburg I, Wunderlich AP, et al. Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging 2006;27:78-87 (Pubitemid 41627952)
16. Virchow R Zur cellulose-frage. Virchows Arch 1854;6:416-26
17. Glenner GG, Terry WD. Characterization of amyloid. Annu Rev Med 1974;25:131-5
18. Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004;279:46363-74
19. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? TRENDS Neurosci 2001;24:219-24 (Pubitemid 32204378)
20. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8
21. Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000;33:95-130
22. Geschwind DH. Tau Phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 2003;40:457-60
23. Green MS, Kaye JA, Ball MJ. The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old. Neurology 2000;54:105-13 (Pubitemid 30038746)
24. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2004;1697:137-42 (Pubitemid 38326767)
25. Jackson GR, Wiedau-Pazos M, Sang TK, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002;34:509-19 (Pubitemid 34628749)
26. Cruz JC, Tseng HC, Goldman JA, et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003;40:471-83 (Pubitemid 37494698)
27. Noble W, Olm V, Takata K, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003;38:555-65 (Pubitemid 36645031)
28. Liou YC, Sun A, Ryo A, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003;424:556-61 (Pubitemid 36975777)
29. Town T, Zolton J, Shaffner R, et al. p35/Cdk5 pathway mediates soluble amyloid-beta peptide induced tau phosphorylation in vitro. J Neurosci Res 2002;69:362-72 (Pubitemid 34809485)
30. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Biol 2001;2:749-59 (Pubitemid 33679837)
31. Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002;22:9340-51 (Pubitemid 35356177)
32. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005;25:5446-54 (Pubitemid 40770926)
33. Kins S, Crameri A, Evans DRH, et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 2001;276:38193-206
34. Durakova Z. Some current insights into oxidative stress. Physiol Res 2010;59:459-69
35. Guglielmotto M, Giliberto L, Tamagno E, et al. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci 2010;2:3
36. Gu F, Zhu M, Shi J, et al. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice. Neurosci Lett 2008;440:44-8
37. Casado A, Encarnacion Lopez-Fernandez M, Concepcion Casado M, et al. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 2008;33:450-8 (Pubitemid 351230446)
38. Perrin R, Briancon S, Jeandel C, et al. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study. Gerontology 1990;36:306-13
39. Pratico D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-92
40. Pappolla MA, Chyan YJ, Omar RA, et al. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998;152:871-83
41. McCord JM. The evolution of free radicals and oxidative stress. Am J Med 2000;108:652-9 (Pubitemid 30336605)
42. Onozato ML, Tojo A, Goto A, et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186-94 (Pubitemid 34075146)
43. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001;40:959-75 (Pubitemid 32530602)
44. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002;18:872-9 (Pubitemid 35292261)
45. Zheng W, Wang SY. Antioxidant activity and phenolic compounds in selected herbs. J Agric Food Chem 2001;49:5165-70 (Pubitemid 33089648)
46. Rezai-Zadeh K, Shytle D, Sun N, et al. Green tea epigallocatechin-3- gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005;25:8807-18
47. Obregon DF, Rezai-Zadeh K, Bai Y, et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 2006;281:16419-28
48. Rezai Zadeh K, Douglas Shytle R, Bai Y, et al. Flavonoid mediated presenilin 1 phosphorylation reduces Alzheimer's disease amyloid production. J Cell Mol Med 2009;13:574-88
49. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57-69 (Pubitemid 46011999)
50. Salganik RI. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 2001;20(Suppl 5):464-77
51. Allan Butterfield D, Castegna A, Lauderback CM. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002;23:655-64 (Pubitemid 35217687)
52. Floyd RA, Carney JM. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 2004;32:S22-7
53. Benard G, Bellance N, James D, et al. Mitochondrial bioenergetics and structural network organization. J Cell Sci 2007;120:838-49
54. Petit PX, Goubern M, Diolez P, et al. Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: the impact of irreversible permeability transition. FEBS Lett 1998;426:111-16 (Pubitemid 28198166)
55. Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c Cell 1996;86:147-57 (Pubitemid 26256586)
56. Jordan J, Cena V, Prehn JHM. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J Physiol Biochem 2003;59:129-41
57. Kann O, Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007;292:C641-9
58. Rusakov DA. Ca2+-dependent mechanisms of presynaptic control at central synapses. Neuroscientist 2006;12:317-28
59. Hollenbeck PJ. Mitochondria and neurotransmission: evacuating the synapse. Neuron 2005;47:331-3 (Pubitemid 41073874)
60. Hauptmann S, Scherping I, Drose S, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 2009;30:1574-86
61. Keller JN, Kindy MS, Holtsberg FW, et al. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 1998;18:687-98
62. Zhu X, Su B, Wang X, et al. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 2007;64:2202-10 (Pubitemid 47347959)
63. Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol 2002;2:120-3 (Pubitemid 44204507)
64. Keller JN, Mark RJ, Bruce AJ, et al. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 1997;80:685-96 (Pubitemid 27334614)
65. Galindo MF, Ikuta I, Zhu X, et al. Mitochondrial biology in Alzheimer's disease pathogenesis. J Neurochem 2010;114:933-45
66. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev 2008;60:1463-70
67. Moreira PI, Harris PLR, Zhu X, et al. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimer Dis 2007;12:195-206 (Pubitemid 47509369)
68. Quinn JF, Bussiere JR, Hammond RS, et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 2007;28:213-25 (Pubitemid 44894634)
69. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421 (Pubitemid 30349107)
70. Abbas N, Bednar I, Mix E, et al. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. J Neuroimmunol 2002;126:50-7 (Pubitemid 34521731)
71. Brown GC, Bal-PriceA. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 2003;27:325-55 (Pubitemid 38156291)
72. Conde JR, Streit WJ. Microglia in the aging brain. J Neuropathol Exp Neurol 2006;65:199-211
73. Fetler L, Amigorena S. Neuroscience: brain under surveillance: the microglia patrol. Science 2005;309:392-402
74. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003;304:1-11
75. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006;147:S232-45
76. Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 2008;12:762-80 (Pubitemid 351718063)
77. De Giorgio LA, Shimizu Y, Chun HS, et al. APP knockout attenuates microglial activation and enhances neuron survival in substantia nigra compacta after axotomy. Glia 2002;38:174-8
78. Tan J, Town T, Crawford F, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 2002;5:1288-93 (Pubitemid 35417763)
79. Tan J, Town T, Mori T, et al. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci 2000;20:7587-95
80. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7 (Pubitemid 29327547)
81. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9 (Pubitemid 30644751)
82. Town T, Laouar Y, Pittenger C, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008;14:681-7 (Pubitemid 351809551)
83. Combs CK, Karlo JC, Kao SC. beta-Amyloid stimulation of microglia and monocytes results in TNF alpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001;21:1179-85
84. Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004;10:719-26 (Pubitemid 38937637)
85. Nagele RG, D'Andrea MR, Lee H, et al. Astrocytes accumulate Abeta42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003;971:197-209 (Pubitemid 36423321)
86. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007;184:69-91 (Pubitemid 46365992)
87. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immun 2005;19:493-9 (Pubitemid 41407697)
88. Simard AR, Soulet D, Gowing G, et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006;49:489-502 (Pubitemid 43221886)
89. Heneka MT, Feinstein DL. Expression and function of inducible nitric oxide synthase in neurons. J Neuroimmunol 2001;114:8-18 (Pubitemid 32184720)
90. Torreilles F, Salman-Tabcheh S, Guerin MC, et al. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Rev 1999;30:153-63 (Pubitemid 29440938)
91. Trejo JL, Carro E, Garcia-Galloway E, Torres-Aleman I. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J Mol Med 2004;82:156-62 (Pubitemid 38392165)
92. Lesort M, Johnson GVW. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 2000;99:305-16 (Pubitemid 30628418)
93. Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003;23:7084-90
94. Mori T, Paris D, Town T, et al. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APPsw mice. J Neuropathol Exp Neurol 2001;60:778-84
95. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-60
96. Mahley RW, Nathan BP, Pitas RE. Apolipoprotein E. structure, function, and possible roles in Alzheimer's disease. Ann NY Acad Sci 1996;777:139-45
97. Hartmann T. Role of Amyloid precursor protein, amyloid-and-secretase in cholesterol maintenance. Cell Mech Alzheimer Dis 2006;3:305-10
98. Wellington CL. Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clin Genet 2004;66:1-16 (Pubitemid 38960816)
99. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 2006;57:513-33 (Pubitemid 43262005)
100. Schmitt B, Bernhardt T, Moeller HJ, et al. Combination therapy in Alzheimers disease: a review of current evidence. CNS Drugs 2004;18:827-44 (Pubitemid 39612014)
101. Ulrich J, Stahelin HB. The variable topography of Alzheimer type changes in senile dementia and normal old age. Gerontology 1984;30:210-4 (Pubitemid 14089745)
102. Klingner M, Apelt J, Kumar A, et al. Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. Int J Dev Neurosci 2003;21:357-69 (Pubitemid 37346400)
103. Grothe M, Zaborszky L, Atienza M, et al. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cerebral Cortex 2010;20:1685-95
104. Fischer W, Gage FH, Bjorklund A. Degenerative changes in forebrain cholinergic nuclei correlate with cognitive impairments in aged rats. Eur J Neurosci 2006;1:34-45
105. Markowska AL, Stone WS, Ingram DK, et al. Individual differences in aging: behavioral and neurobiological correlates. Neurobiol Aging 1989;10:31-43 (Pubitemid 19164498)
106. Borson S, Barnes RF, Veith RC, et al. Impaired sympathetic nervous system response to cognitive effort in early Alzheimer's disease. J Gerontology 1989;44:M8-12
107. Olton DS. Interventional approaches to memory. In: Martinez JR, Kesner RP, editors, Lesions in learning and memory: a biological view. Academic Press, Orlando, FL; 1986. p. 379-97
108. Handelmann GE, Olton DS. Recovery of function after neurotoxic damage to the hippocampal CA3 region: importance of postoperative recovery interval and task experience. Behav Neural Biol 1981;33:453-64 (Pubitemid 12175952)
109. Coyle JT. Neurotoxic action of kainic acid. J Neurochem 1983;41:1-11 (Pubitemid 13064890)
110. Beninger RJ, Jhamandas K, Boegman RJ, et al. Effects of scopolamine and unilateral lesions of the basal forebrain on T-maze spatial discrimination and alternation in rats. Pharmacol Biochem Behav 1986;24:1353-60 (Pubitemid 16067421)
111. Troncoso JC, Price DL, Griffin JW, et al. Neurofibrillary axonal pathology in aluminum intoxication. Ann Neurol 2004;12:278-83
112. Wenk GL. An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers. Psychopharmacology 1989;99:431-8 (Pubitemid 19273095)
113. Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002;71:2489-98 (Pubitemid 35251893)
114. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Academic Press, Orlando, FL; 2007
115. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 1988;256:283-90
116. Issa AM, Gauthier S, Collier B. Effects of calyculin A and okadaic acid on acetylcholine release and subcellular distribution in rat hippocampal formation. J Neurochem 2002;72:166-73
117. Gong CX, Wang JZ, Iqbal K, et al. Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neurosci Lett 2003;340:107-10 (Pubitemid 36369286)
118. Bernstein HG, Schwartzberg H, Poeggel G, et al. Intracerebroventricular but not intraperitonial administration of aluminium attenuates vasopressin-enhanced retrieval of a passive avoidance task in rats. Pharmacol Biochem Behav 1994;47:587-90 (Pubitemid 24077729)
119. Kumar MVK, Gupta YK. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav 2002;73:565-71 (Pubitemid 34879162)
120. Kumar A, Seghal N, Naidu PS, et al. Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacol Rep 2007;59:274-82
121. Elder GA, Sosa MAG, De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med 2010;77:69-81